The effects of different patient factors and dose levels of chemotherapeutic agents on clinical outcomes in advanced gastric cancer are not as yet fully characterized. We aimed at developing an integrative model that incorporates dose and covariate information to predict tumor growth and patient survival in advanced gastric cancer patients treated with trastuzumab (T), 5-FU(F)/capecitabine (X) (F or X), and cisplatin (P). Sixty-nine patients (training dataset) were used for model building and a separate 86 patients (test dataset) for model validation. A fraction of tumor cells sensitive to each drug was incorporated as a model parameter, and T was assumed as cytostatic and X/F and P as cytotoxic. Cox proportional hazards analyses were performed on model parameters and patient covariates. The model well described the time course of observed tumor size changes, and revealed that the pretreatment tumor growth rate constant k g , which was formulated as a function of pretreatment disease duration and baseline tumor size, was positively correlated with baseline tumor size (p = 0.0084) and histologic grade (p = 0.034), and the efficacy of 5-FU with body weight (p < 2e−16) and that of cisplatin with histologic grade (p = 0.00013). Prior gastrectomy and Eastern Cooperative Oncology Group scores were significant prognostic factors for progression-free survival (PFS). For hazards analysis, a unit increase of k g was associated with a relative risk of 3.19 for PFS (p = 0.00055) and 4.45 for OS (p = 2e−04) in the test dataset, with a similar trend observed in the training dataset. Dose-response simulations showed that, for small baseline tumor size or low histologic grade, a maximum cytotoxic effect was attainable with a dose smaller than the current recommended dose.
INTRODUCTION
In 2010, the Food and Drug Administration granted approval for trastuzumab in combination with cisplatin and fluoropyrimidine for the treatment of patients with human epidermal growth factor receptor 2 (HER2) overexpressing/ amplified metastatic gastric cancer based on a significant improvement of median overall survival (OS) in the Trastuzumab for Gastric Cancer (ToGA) clinical trial (1) . Since then, efforts to investigate its dose-response relationship and identify factors that significantly affect the patient prognosis have been made. As a result, a study of trastuzumab in advanced gastric cancer (2) has recently revealed that patients with the lowest trough concentration had a shorter OS and the highest rate of progressive disease (PD). This study, however, did not investigate the efficacies of cytotoxic agents and their possible synergy with trastuzumab. Accordingly, as yet, dose-response relationships of the trastuzumab-based combination chemotherapy and factors that affect the treatment response have not been fully elucidated.
As for prognostic factors in advanced cancer, the most widely used index is that proposed by the Royal Marsden Hospital (RMH) (3) consisting of four risk factors: performance score ≥ 2, liver metastases, peritoneal metastases, and alkaline phosphatase ≥ 100 UI/L. This index was later validated in the REAL-2 trial (4) . Subsequent reports proposed the number and location of metastases (5) and the lactate dehydrogenase level (6) as significant risk factors. These prognostic factors, however, do not directly address underlying tumor biology and mostly reflect clinical correlations rather than cause and effect. Hence, recently there has been an increasing interest in considering dynamic aspects of the disease for assessing the patient prognosis. Several cancer types have shown that early tumor shrinkage (7) and depth of response (DoR) (8, 9) to chemotherapy are significantly correlated with the patient prognosis. This indeed suggests that tumor size dynamics provide a new dimension to predicting clinical outcomes.
Since cancer is primarily a disease characterized by abnormal cell growth and invasion to other parts of the body, tumor growth rate is one of the primary determinants of longterm prognosis. The use of tumor growth rate in assessing the patient prognosis, however, is hampered by the difficulty of its estimation since, in chemotherapy-treated patients, initial tumor shrinkage can mask underlying tumor growth. It is only when the tumor begins to regrow after resistance development that its underlying growth rate was revealed. Such a time lag can be critical considering the rapid disease progression of advanced gastric cancer. Only recently has assessing the patient prognosis using the model-based estimate of tumor growth rate (10) received attention in major scientific journals.
In this study, we have undertaken pharmacodynamic modeling of serial tumor size under a nonlinear mixed effects modeling framework to investigate dose-response relationships of cytotoxic agents and trastuzumab in HER2-positive metastatic gastric cancer. We then tried to link the model output with patient survival with particular emphasis on assessing the prognostic significance of model-predicted intrinsic (i.e., pretreatment) tumor growth rate.
MATERIALS AND METHODS

DATA
The training dataset used for modeling consists of 69 patients who participated in a clinical trial conducted from December 2005 in Severance Hospital, Seoul, Korea, as part of the multicenter ToGA phase III clinical trial (1) .
Patients whose gastric adenocarcinomas showed HER2 overexpression by immunohistochemistry (IHC) or gene amplification by fluorescence in situ hybridization were eligible. Then, eligible patients were randomized to one of the following two groups (1): X/F+P versus X/F+P+T (B/m eans OR and B+^means AND, and X, F, T, and P denote capecitabine, 5-FU, trastuzumab, and cisplatin, respectively). Capecitabine (which is a prodrug of 5-FU) was assumed to have the same effect as 5-FU.
Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.0 evaluation (11) took place approximately every 3 weeks, yielding tumor size measurements, ranging from 2 to 18 with the median of five measurements.
For model validation, 86 patients who participated in three different clinical studies from May 2009 to April 2016 conducted in Severance Hospital, Seoul, Korea, were pooled into a test dataset. The study protocol was approved by the Institutional Review Board of Severance Hospital and was identical to that of the ToGA clinical trial, except that, for patients enrolled after year 2012, RECIST version 1.1 was used (12) instead of Version 1.0. Forty-two were treated with X/F/TS-1+P+T while 44 were given X/F/TS-1+oxaliplatin/ cisplatin.
TUMOR SIZE ANALYSIS Tumor Size Model
Assuming tumor cells are heterogeneous in drug sensitivity, the tumor size model was described as
S, D, and R denote tumor sizes for treatment-sensitive, damaged, and resistant tumor cells; N the observed tumor size, Eff Sta and Eff Tox the effects of cytostatic (i.e., trastuzumab) and cytotoxic drugs (i.e., 5-FU/capecitabine and platinum agents), respectively, and the unperturbed or pretreatment tumor growth rate constant k g given by
where τ is the pretreatment disease duration, N(t base ) is the baseline tumor size, and t base is the time of baseline RECIST evaluation within 4 weeks of enrollment into clinical trial. Equation (5) is formulated based on the following reasoning: define τ = t base − t 0 as an estimate of disease duration prior to treatment where t 0 is the reference time of tumor size reaching the detectable size of unit length (i.e., 1 mm). Then, based on the exponential growth equation, the baseline tumor size becomes
Normalizing it so that N(0) = 0 when k g = 0 or τ = 0, it becomes
Solving for k g leads to Eq. (5). Now, sensitive cells (S) were sub-partitioned into three groups as follows: Then, the initial tumor size of each cell group, denoted as S 1 (0), S 2 (0), and S 3 (0), with S(0) = S 1 (0) + S 2 (0) + S 3 (0), can be written as
&
In addition,
Fr_P and Fr_F represent the fraction of N(0) resistant to cisplatin and 5-FU/capecitabine, respectively.
Drug Effect Model
Cytotoxic effect is often associated with a delay in onset time. Simeoni et al. (13) accounted for this time lag using three transit compartments. In our study, a single transit compartment denoted by D in Eq. (2) was used. Unlike cytotoxic effect, no time lag was assumed in cytostatic effect.
Drug effect was modeled using Dose s , the dose normalized by a standard dose (Dose s = dose/standard dose), as follows.
k eff_T , k eff_P , and k eff_F are rate constants for drug efficacy of trastuzumab, cisplatin, and 5-FU/capecitabine, respectively, and Eff Syn denotes the synergistic effect between cisplatin and trastuzumab (14) , formulated as
where k Eff_Syn is a rate constant for synergistic efficacy between the two drugs. While it is often difficult to estimate each drug effect separately using data collected during concomitant chemotherapy, this was possible with our particular dataset because (i) both trastuzumab-treated and nontreated groups existed, and (ii) doses of cisplatin and 5-FU analogues were tapered in some patients due to toxic effects, allowing differential estimation of the two drug effects.
Analytic Solution for Tumor Size Model
Differential equations in Eqs. (1)- (4) are computationally intensive, and we developed an analytic solution of N(t) as in Eq. (18) , which was used during model development. See Supplementary Material for derivation.
where g, i, and r represent k g , Eff Sta , and Eff Tox , respectively.
Inter-individual Variability Model
One important advantage with a population model developed within the nonlinear mixed effect model framework is its ability to incorporate individual variability in drug response inexplicable by model parameters, which was formulated as follows.
where P and TVP are individual and typical values of a parameter, respectively, and η is the inter-individual variability-related random difference assumed to be normally distributed as N(0,ω 2 ).
Covariate Selection
Out of 69 patients in the training dataset, 3 were HER2-negative (IHC 0, 2; IHC 1+, 1), 13 were borderline (IHC 2+), and 42 were positive (IHC 3+). HER2 status was categorized into HER2-L with IHC HER2 < 3+ and HER2-H with IHC HER2 3+.
HER2 positivity, histologic grade, organ sites of metastases, baseline tumor marker levels (CEA, CA19-9, CA72-2), the history of gastrectomy, Eastern Cooperative Oncology Group (ECOG) score, age, body weight, and gender were inspected as candidate covariates. Covariate search was done using stepwise selection based on the likelihood ratio test with the criteria of p < 0.05 for forward addition and p < 0.01 for backward deletion. When stepwise selection was not successful, covariates that led to statistically significant drops of Akaike information criterion with p < 0.05 were selected.
SURVIVAL ANALYSIS Survival Model Analysis
Survival model analysis was performed for progressionfree survival (PFS) and postprogression survival (PPS) using various baseline hazard functions, including constant, Weibull, log-logistic, and Gompertz functions, and covariate selection was undertaken as described above, with the censoring model being incorporated. In particular, in PFS modeling, PD diagnosis associated with nonmeasurable lesions (e.g., bone infiltration, ascites) was taken into account. That is, defining PD 1 by a 20% increase in tumor 
Cox-Proportional Hazards Regression Survival Analysis
Cox-proportional hazards regression analysis was then performed using tumor size model parameter estimates and patient covariates. This analysis was intended to examine prognostic factors on patient survival without directly estimating baseline hazard, which is an often used approach in clinical oncology. In so doing, given that the tumor growth rate constant was reported as a potential predictor of survival (10) , in addition to k g , the growth rate constant incorporating the cytostatic effect of trastuzumab k g_i was selected as tumor size model parameters to be tested, which was defined as
Kaplan-Meier Analysis
Lastly, Kaplan-Meier analysis was performed for graphical examination.
MODEL EVALUATION
The final model was evaluated using posterior predictive check (PPC) (15) given 1000 datasets simulated from the developed model. DoR was chosen as the target statistic, which was calculated as
Tumor size at best response Baseline tumor size ð21Þ
Additionally, with the 1000 datasets simulated above, the final model was evaluated using a visual predictive check The notations are as follows: τ, disease duration; Fr_F, resistant fraction to X/F; Fr_P, resistant fraction to P; k eff_T , k eff_P , and k eff_F : drug efficacy of trastuzumab, cisplatin, and 5-FU/capecitabine, respectively; k eff_Syn , synergistic efficacy between trastuzumab and cisplatin. Note that τ is a function of k g defined by k g = 1 τ log(1 + N(t base )) (see Eq. (5)) WT body weight a It was coded as τ = θ/HIST, with the estimate and relative SE of θ being 105.64 and 32.6%, respectively, and HIST being an indicator variable with values of 1, 2, 3, and 4 for grades I, II, III, and IV, respectively b It was coded as ω Fr_F was common to ECOG = 0 and ECOG = 1/2/3 (VPC) (16) . The 95% confidence interval of the predicted percentiles was used to help determine the agreement between observations and predicted percentiles. VPC was also conducted using PFS and PPS as endpoints.
DOSE-RESPONSE SIMULATION
To investigate the benefit of a higher dose of trastuzumab and cytotoxic dose reductions in chemotherapy, dose-response curves were generated under a range of different doses for trastuzumab and cytotoxic drugs based on the developed model using DoR as the response variable.
SOFTWARE
Tumor size and survival models were fitted using NONMEM version 7.3. R (RStudio), and Python 2.7 was used for data exploration, analysis, and simulation. Cox proportional hazards regression was performed using the survival package in R. Table I summarizes the demographics and covariates of patients in each dataset, along with the dose ranges of the drugs. No significant delays or postponements of drug administration occurred during the studies. The table shows that baseline tumor size was significantly different between the training set and the test set, which was associated with using different RECIST versions. To deal with the discrepancy, before the analysis, all baseline measurements using RECIST version 1.1 were rescaled by 1.72, which is the known reported mean ratio of the sum of the longest diameter measurements between RECIST version 1.0 and 1.1. We have confirmed that after this transformation, the distributions of baseline values were similar, yielding mean values of 94.60 and 98.46 mm in the training and test datasets, respectively, with a p value of 0.7546. The numbers (%) of patients evaluated based on RECIST 1.0 and 1.1 were 24 (27.91%) and 62 (72.09%), respectively. For treatment response to each drug, it was found that k eff_F was significantly lower for underweight patients (WT ≤ 60 kg for males and WT ≤ 50 kg for females) than normal-weight patients, yielding 3.00 versus 4.51 month Fig. 3 . Tumor size model evaluation using posterior predictive checks with 1000 replicates using a training and b test datasets. Yellow, blue, and green histograms denote 20, 50, and 80% of the predicted depths of response. Red vertical bars represent corresponding percentiles of the observed depths of response for histologic grades I, II, III, and IV, respectively (p = 0.00013). A significant synergistic effect was found between cisplatin and trastuzumab (p = 0.044). Standard doses of cisplatin and trastuzumab given together led to an increase in Eff To x (i.e., cytotoxic effect) by 0.33 month −1 (i.e., decrease in half-life by 2.10 months). The ECOG score was found to significantly affect Fr_F. The greatest sources of treatment response variability were found to stem from Fr_P and Fr_F, with inter-individual variances of Fr_P and Fr_F (ECOG = 0) being 100.89 and 71.15%, respectively.
RESULTS
PATIENT CHARACTERISTICS
Goodness-of-fit plots for the final tumor size model were assessed using mirror plots of tumor size observations and post hoc Bayesian individual predictions stratified by baseline tumor size and histologic grade in the training dataset (see Fig. 1 ). It can be seen that our model provides sufficient flexibility to fit most of the observations. There is a tendency of a larger terminal slope of the regrowth phase in patients with larger baseline tumor size (i.e., > 100 mm) and higher histologic grades.
VPC results also show that observations were well included in the 95% confidence interval of the predicted percentiles (see Fig. 2 ). PPC results show that 20, 50, and 80% of the observed DoR coincided reasonably well with the corresponding percentiles of the predictions (Fig. 3) .
The NONMEM code for the tumor size model is provided in the Supplementary Material.
SURVIVAL ANALYSIS Survival Model Analysis
The PD model for nonmeasurable lesion was best described by a log-logistic hazard; the PFS model for censored events and PPS models by Weibull hazard (Table III) . For the PD model of nonmeasurable lesion, the hazard decreased by 85% (=e −1.89 − 1) with prior gastrectomy and increased by 139% (= e 0.87 − 1) with a unit increase in ECOG score. For the PPS model of all events, the hazard decreased by 6.01% (= e −0.062 − 1) per monthly increase of PFS and increased by 42% (= e 0.35 − 1) per 1 standard deviation increase on the last RECIST measurement. Weibull hazard function produced a shape parameter of 2.16 for PFS-censored events, indicating that the hazard of PD increases with time (or the hazard of censoring decreases with time), and 0.78 and 0.66 for the PPS model for all and censored events, respectively, indicating that the hazard of death is highest immediately after PD and tends to decrease thereafter.
VPC additionally performed for PFS and PPS showed good agreement between observations and model predictions for both training and test datasets (Fig. 4) .
Cox-Proportional Hazards Regression Survival Analysis
Analysis of All Lesions
In univariate analysis, both k g , pretreatment tumor growth rate constant, and k g_i , the growth rate constant incorporating a cytostatic effect of trastuzumab, were significantly correlated with survival. Table IV summarizes additional covariates that were found significant for PFS, PPS, and OS. k g was significant in all of PFS, PPS, and OS, with unit increase being associated with a relative risk of 3.19 (p = 0.00055), 3.93 (p = 0.00028), and 4.45 (p = 2e−04) in the training dataset, and 2.57 (p = 0.0066), 2.82 (p = 0.013), and 3.33 (p = 0.0024) in the test dataset for PFS, PPS, and OS, respectively. For multivariate analysis, only k g_i in PFS was significant in both datasets (p < 0.002) ( Table IV) .
Analysis of Measurable vs Nonmeasurable Lesion for PFS
For univariate analysis, k g, i was found significant for measurable lesions in both training (p = 0.0018) and test datasets (p = 9e−05) whereas prior gastrectomy was found significant for nonmeasurable lesions in both training (p = 0.0087) and test datasets (p = 0.026) (Table IV) . Similar results were acquired using multivariate analysis.
Kaplan-Meier Analysis
For PFS, k g, i > 1.0 year −1 yielded a relative risk of 3.21 (p = 2.3e−05) and 2.79 (p = 1e−04) in the training and test datasets, respectively, with a 1-year progression-free rate of 10% in both datasets, whereas the reference group was associated with 50 and 40% in each dataset.
For PPS, k g, i > 1.0 year −1 yielded a relative risk of 3.15 (p = 0.00077) and 2.85 (p = 0.017) in the training and test datasets, respectively, with a 1-year survival of 10 and 30% in 
Covariate notations are as follows: PD nonmeasurable : Gas = 1 for gastrectomy history and Gas = 0 otherwise PPS All : HISTG = 0 for HIST < 3 and HISTG = 1 otherwise, LSIZE = tumor size at last RECIST assessment, LSIZE Mean = 68.3, LSIZE SD = 72.4,P FS = predicted PFS each dataset whereas the reference group associated with 60 and 50%, respectively. The Kaplan-Meier curves are shown in Fig. 5 .
DOSE-RESPONSE SIMULATION
Dose-response simulations are shown in Fig. 6 . Figure 6a shows results of altering the doses of either cytotoxic drugs (left) or trastuzumab (right) in the absence of other drugs. Figure 6b shows results of dose alteration of cytotoxic drugs (left) and trastuzumab (right) when given with standard doses of trastuzumab (left) and cytotoxic drugs (right). Figure 6c , d is identical to Fig. 6a , b except that treatment responses were stratified on histologic grade instead of baseline tumor size.
Results show that (i) the dose needed to attain a maximum cytotoxic effect increases with baseline tumor size and histologic grade and (ii) the maximum cytotoxic effect can be attained with a dose less than the current standard dose. As an illustration, if the baseline tumor size is 20 mm, about 66% of the maximum DoR can be achieved with only 10% of the standard cytotoxic dose as compared to 69% of the maximum DoR achieved with 100% of the standard dose (Fig. 6b, left) . If the histologic grade is 1, the maximum DoR can be achieved with only 10% of the standard cytotoxic dose (Fig. 6d, left) .
DISCUSSION
Although trastuzumab has become a standard regimen for HER2-positive metastatic gastric cancer patients, treatment responses to T+XP/FP chemotherapy are highly variable. A nonlinear mixed effects model (17) was built to identify the sources and magnitudes of such variability.
Overall, training and test datasets showed similar patient characteristics. A significant difference seen for baseline tumor sizes is likely due to using different RECIST versions. The number and sum of tumor diameters of the target lesions are known to be significantly lower in RECIST 1.1 than 1.0 (12) . The reported value of 1.72 for the ratio of version 1.0 to 1.1 for the sum of tumor diameters was similar to the ratio Fig. 4 . VPC of progression-free survival (a, c) and postprogression survival (b, d) for training (a, b) and test (c, d) datasets (n = 1000). Red lines are simulated KM curves, and blue lines are observed KM curves calculated using our datasets (1.75). Note however that our model performs nearly as well in the test dataset as seen in Figs. 2, 3, and 4 .
When modeling the tumor size, the first issue was selection of an appropriate tumor growth model. In the literature, tumor growth is often described using one of the following: (i) exponential growth model, (ii) logistic growth model, and (iii) Gompertz growth model. There are, of course, other versions such as models assuming an initial exponential growth phase followed by a linear growth phase (13) . However, since our tumor size observations are censored beyond PD diagnosis, the late phase growth could not be accounted for. Hence, for both simplicity and practicality, we settled with the exponential growth assumption.
Another important issue was deciding the mode of action of each of the drugs used. While we assumed a mainly cytostatic mode of action for trastuzumab, in reality, no drug would be either purely cytostatic or cytotoxic. For example, trastuzumab is known to exert cytotoxic effect to a certain degree, especially in patients with high HER2 expression levels. However, we believe that such cytotoxic effect plays a minor role. If it did not, trastuzumab would be as effective as other cytotoxic agents in achieving tumor regression when given alone.
According to our tumor size model, cisplatin induces faster tumor shrinkage in patients with higher histologic grade. This could seem counterintuitive at first, but becomes understandable if one recalls that cytotoxic effects are more pronounced in cells with a higher growth fraction. Dependence of 5-FU efficacy on patient body weight can also be explained from decreased tumor growth fraction in cachexic patients. Drug sensitivity, in our work, was defined as a fraction of cells sensitive to a given treatment. Parameter estimates reported in Table II shows that about 56% of the tumor cells are resistant to platinum and 52% (ECOG = 0) and 83% (ECOG > 0) of cells are resistant to 5-FU. Assuming no cross-resistance, this translates to a 71% (= 1 − 0.56 * 0.52) probability of responding to a combination therapy of XP or FP for patients with ECOG = 0 and a 54% (= 1 − 0.56 * 0.83) probability for patients with ECOG > 0. If cross-resistance exists, this probability would be lower. If the resistance to cisplatin always accompanies the resistance to 5-FU (and vice versa), the probability of response to a combination of XP or FP would be 46% (= 1 − 0.56) for ECOG = 0 and 17% (= 1 − 0.83) for ECOG > 0. Reality would be somewhere in between, with expected response rates of 46~71 and 17~54% for ECOG = 0 and ECOG > 0 patients, respectively. In survival model analysis, various functions were used to describe the time-varying nature of the hazard. For the PFS-censoring event, the hazard of PD seems to increase with time. As for patient death after PD diagnosis, the opposite seems true. The former is likely because various causes of PD tend to accumulate over time. As for the latter, this might be due to survivorship bias. Patients are switched to second-line agents after PD diagnosis, which can falsely lead to more censored events even if these second-line agents are not effective and there is a high likelihood that some of these patients die sooner or later.
In Cox-proportional hazards regression survival analysis, k g and k g, i were generally associated with significantly lower p values than other known prognostic factors. Since both indices can be easily calculated before the treatment using Eqs. (5) and (12), they could be used as efficient prognostic indices of treatment outcomes. When compared, k g, i was a more significant predictor of PFS than k g while just the opposite was true for PPS. This result is as expected since PFS is a clinical outcome reflecting the response to 1st-line chemotherapy consisting of trastuzumab while PPS reflects the response to 2nd-or 3rd-line chemotherapy without trastuzumab.
The cause of prior gastrectomy being associated with a lower risk of nonmeasurable PD is unclear. It is possible that this was due to lower trastuzumab clearance in these patients (2) . Another possibility is that the removal of the stomach leads to less chance of tumor cells spreading to the peritoneum. Neither k g nor k g, i was a significant predictor of nonmeasurable PD. This suggests different biological processes governing measurable and nonmeasurable lesion progression.
Cisplatin is notorious for its high incidence of adverse effects and toxicities (18) . Although perhaps not as much as cisplatin, 5-FU is not exempt from such side effects (19) . The results of dose-response simulations suggest that cytotoxic drug effect critically depends on baseline tumor size, histologic grade, and most importantly the concomitant use of trastuzumab. When given with a standard dose of trastuzumab in patients harboring small baseline tumor sizes with low histologic grades, cytotoxic drug doses might be carefully reduced to improve treatment tolerability. Incorporating the survival model of drug discontinuation, the tumor size model was simulated to obtain the predicted DoR under two scenarios: (i) no discontinuation, and (ii) discontinuation of cytotoxic drugs, which are as shown in Supplementary Table 1 . The results indicate that when the histologic grade is I, discontinuation of cytotoxic agents has virtually no effect on DoR when trastuzumab is given together. This is in agreement with our doseresponse simulation results. For a histologic grade greater than or equal to II, discontinuation of cytotoxic agents does have an adverse effect on DoR. To summarize, discontinuation of cytotoxic agents when given with trastuzumab is a relatively safe decision when the histologic grade is low and the baseline tumor size is small. On the other hand, discontinuation of cytotoxic agents results in a significant reduction in DoR when the histologic grade is high. Therefore, every effort should be made to adequately treat side effects and postpone the timing of drug discontinuation when the histologic grade is high and/ or the baseline tumor size is large.
Although not addressed in the results presented so far, drug toxicity, which is a major reason for drug withdrawal in chemotherapy, is another important issue in cancer treatment. In this regard, we investigated the time to drug withdrawal for cytotoxic drugs and resulting influences on treatment outcomes. First, Kaplan-Meier survival curves of cisplatin and 5-FU/capecitabine discontinuation were examined, which are shown in Supplementary Fig. 1 . In the figure, it was seen that about 50% of patients eventually discontinue 5-FU/capecitabine whereas for cisplatin, nearly all the patients discontinue its use by 15 months into therapy. Hence, the hazard of cisplatin discontinuation was found to be much higher than that of 5-FU/capecitabine. Then, parametric survival models were built to search for factors that affect the hazard of drug discontinuation. It was found that female gender increased the risk of discontinuation of both drugs, significantly (p = 0.05) for 5-FU/capecitabine and marginally significantly (p = 0.06) for cisplatin (model code not shown).
In this work, as for metastatic spreading, we were not able to carry out full-blown modeling of metastatic burden where the metastatic emission rate is assumed as being proportional to primary tumor size (20) because all target lesions were only measured up to the point of PD diagnosis. Instead, the risk of metastasis was assessed based on PD events diagnosed on the appearance of new lesions and the time to metastatic event was analyzed, identifying prior gastrectomy and ECOG as significant factors (Table III) . If target lesions can be measured beyond the point of PD diagnosis also, an extension of our model to describe the dynamics of metastatic burden after PD diagnosis would be useful in that premetastatic and postmetastatic growth rates could be compared and predicted. In this regard, the apparent tumor growth rate is expected to lead to a progressive increase according to clonal evolution (21) , and modeling such progression would be helpful in predicting clinical outcomes in different stages of the disease.
The lack of PK measurement is a major limitation of our study. Actually, a K-PD model was initially tried (22) but the result was not successful even if the elimination rate constant from the virtual compartment was assumed to be common to all drugs (due to numerical difficulty). This was because our tumor size measurements were obtained only at each dosing time, with no measurement taken within a dosing interval, which made it inappropriate to use a K-PD model. Eventually, the model was simplified to using the mean dose over all dosing intervals.
Small sample size and large uncertainty associated with the predicted sensitivity profiles of the patient population (Fig. 3) are additional limitations of our work, which might have caused inaccuracy in k g . The biggest limitation, however, would be in the retrospective study design. Since patients were only followed up until PD diagnosis, poor responders were earlier to finish the study. Under-representation of poor responders in our dataset might have led to biases in model parameter estimates.
Our study shows how computational modeling can be used to infer an important tumor biological parameter with high prognostic value, synthesize information inherent in different patient covariates, and elucidate complex doseresponse relationships. This would be immensely useful not only in the clinical setting but also in designing more efficient clinical trials in oncologic drug development.
CONCLUSION
The tumor growth rate constant constitutes an efficient prognostic index in HER2-positive metastatic gastric cancer patients. In patients with small baseline tumor sizes and low histologic grades treated concomitantly with trastuzumab, cytotoxic drug doses might be reduced to increase treatment tolerability.
